Skip to content
10-Q

Quarterly Report

Oncotelic Therapeutics, Inc. OTLC

0001493152-25-023834

← back to feed
Filed
Nov 17, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 13, 2025 440.78M sh
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$600.13K
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$636.39K
Cash And Equivalents Q3 2025 · Sep 30, 2025 $409K
Cash And Equivalents Q3 2025 · Dec 31, 2024 $86.13K
Stockholders Equity Q3 2025 · Sep 30, 2025 $9.05M
Stockholders Equity Q3 2025 · Dec 31, 2024 $8.25M
Current Liabilities Q3 2025 · Sep 30, 2025 $20.08M
Current Liabilities Q3 2025 · Dec 31, 2024 $19.2M
Total Liabilities Q3 2025 · Sep 30, 2025 $20.08M
Total Liabilities Q3 2025 · Dec 31, 2024 $19.2M
Current Assets Q3 2025 · Sep 30, 2025 $1.61M
Current Assets Q3 2025 · Dec 31, 2024 $134.21K
Total Assets Q3 2025 · Sep 30, 2025 $28.16M
Total Assets Q3 2025 · Dec 31, 2024 $26.68M
Eps Basic Q3 2025 · Sep 30, 2025 $0.00
Eps Basic Q3 2025 · Sep 30, 2025 $0.00
Eps Basic Q3 2025 · Sep 30, 2024 −$0.01
Eps Basic restated Q3 2025 · Sep 30, 2024 $0.00
Sga Expense Q3 2025 · Sep 30, 2025 $490.55K
Sga Expense Q3 2025 · Sep 30, 2025 $657.02K
Sga Expense Q3 2025 · Sep 30, 2024 $80.28K
Sga Expense Q3 2025 · Sep 30, 2024 $343.35K
Net Income Q3 2025 · Sep 30, 2025 −$1.05M
Net Income Q3 2025 · Sep 30, 2025 −$1.07M
Net Income Q3 2025 · Sep 30, 2024 −$3.3M
Net Income Q3 2025 · Sep 30, 2024 −$3.92M
Operating Income Q3 2025 · Sep 30, 2025 −$490.97K
Operating Income Q3 2025 · Sep 30, 2025 −$658.04K
Operating Income Q3 2025 · Sep 30, 2024 −$3.28M
Operating Income Q3 2025 · Sep 30, 2024 −$3.54M
Stock Issued Q3 2025 · Jul 31, 2025 2.25M sh
Stock Issued Q3 2025 · Jul 31, 2025 2.25M sh